Scholarlink

<p>Both solid and hematological malignancies are recognized as complex ecosystems in which the tumor microenvironment (TME) plays a pivotal role in mediating therapeutic resistance. TME-driven modulation of BCL2-family proteins has emerged as a key determinant of treatment response in B-cell malignancies. Here, we focused on the regulation of the pro-apoptotic BH3-only protein BIM, using mantle cell lymphoma (MCL), an aggressive and incurable B-cell neoplasm, as a cellular model. Comparative analysis of circulating and lymph node samples highlighted selective BIM downregulation in malignant cells within the nodal TME, contrasting with BIM upregulation observed with normal B cells. TME-mimicking ex vivo co-culture of primary samples recapitulated this tumor-specific and microenvironment-dependent mechanism. Mechanistically, we found that BIM downregulation is driven by a lymphoma-specific CD40L-mediated rewiring of the PI3K/AKT pathway, which in turn inhibits the transcriptional activity of FOXO1. Functionally, CRISPR/Cas9-mediated deletion of BIM in MCL primary cells was sufficient to bypass their dependence on microenvironmental survival cues, leading to long-term autonomous expansion ex vivo. Moreover, BIM loss conferred broad resistance to chemotherapy and clinically relevant targeted agents. In contrast, treatment with bispecific T-cell engagers elicited robust cytotoxic responses regardless of BIM expression, underscoring the potential of immunotherapies to overcome TME-induced apoptotic resistance.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival

  • 期刊论文

  • 发表日期：

    2026年2月19日

查看全文
  • Candice Madiot,
  • Céline Bellanger,
  • Christelle Dousset,
  • Salomé Decombis,
  • Laura Thirouard,
  • Antonin Papin,
  • Estelle Baron,
  • Julien Barc,
  • Yannick Le Bris,
  • Patricia Gomez-Bougie,
  • Agnès Moreau-Aubry,
  • Benoit Tessoulin,
  • Catherine Pellat-Deceunynck,
  • David Chiron

摘要

Both solid and hematological malignancies are recognized as complex ecosystems in which the tumor microenvironment (TME) plays a pivotal role in mediating therapeutic resistance. TME-driven modulation of BCL2-family proteins has emerged as a key determinant of treatment response in B-cell malignancies. Here, we focused on the regulation of the pro-apoptotic BH3-only protein BIM, using mantle cell lymphoma (MCL), an aggressive and incurable B-cell neoplasm, as a cellular model. Comparative analysis of circulating and lymph node samples highlighted selective BIM downregulation in malignant cells within the nodal TME, contrasting with BIM upregulation observed with normal B cells. TME-mimicking ex vivo co-culture of primary samples recapitulated this tumor-specific and microenvironment-dependent mechanism. Mechanistically, we found that BIM downregulation is driven by a lymphoma-specific CD40L-mediated rewiring of the PI3K/AKT pathway, which in turn inhibits the transcriptional activity of FOXO1. Functionally, CRISPR/Cas9-mediated deletion of BIM in MCL primary cells was sufficient to bypass their dependence on microenvironmental survival cues, leading to long-term autonomous expansion ex vivo. Moreover, BIM loss conferred broad resistance to chemotherapy and clinically relevant targeted agents. In contrast, treatment with bispecific T-cell engagers elicited robust cytotoxic responses regardless of BIM expression, underscoring the potential of immunotherapies to overcome TME-induced apoptotic resistance.